Last reviewed · How we verify
Topiramate Slow
At a glance
| Generic name | Topiramate Slow |
|---|---|
| Sponsor | Janssen Korea, Ltd., Korea |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder (PHASE4)
- Topiramate for Alcohol Use in Posttraumatic Stress Disorder (NA)
- Multicentre Study on Rapid Versus Slow Withdrawal of Antiepileptic Monotherapy (NA)
- Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder (PHASE4)
- An Efficacy and Tolerability Study of Topiramate in Participants With Migraine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topiramate Slow CI brief — competitive landscape report
- Topiramate Slow updates RSS · CI watch RSS
- Janssen Korea, Ltd., Korea portfolio CI